SAFETY DATA SHEET
Olmesartan / Hydrochlorothiazide Formulation

SECTION 1. IDENTIFICATION

Product name: Olmesartan / Hydrochlorothiazide Formulation
Other means of identification: No data available

Manufacturer or supplier’s details
Company name of supplier: Organon & Co.
Address: 30 Hudson Street, 33nd floor
               Jersey City, New Jersey, U.S.A 07302
Telephone: 551-430-6000
Emergency telephone: 215-631-6999
E-mail address: EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical
Restrictions on use: Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations
Reproductive toxicity: Category 1A
Specific target organ toxicity - repeated exposure: Category 1 (Kidney, Parathyroid gland)

GHS label elements
Hazard pictograms:

Signal Word: Danger
Hazard Statements: H360D May damage the unborn child.
                     H372 Causes damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.
Precautionary Statements: Prevention:
                         P201 Obtain special instructions before use.
                         P202 Do not handle until all safety precautions have been read and understood.
                         P260 Do not breathe dust.
                         P264 Wash skin thoroughly after handling.
                         P270 Do not eat, drink or smoke when using this product.
                         P280 Wear protective gloves, protective clothing, eye protection and face protection.
Response: P308 + P313 IF exposed or concerned: Get medical attention.
SAFETY DATA SHEET

Olmesartan / Hydrochlorothiazide Formulation

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>Common Name/Synonym</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olmesartan</td>
<td>No data available</td>
<td>144689-63-4</td>
<td>&gt;= 5 - &lt; 10 *</td>
</tr>
<tr>
<td>Cellulose</td>
<td>No data available</td>
<td>9004-34-6</td>
<td>&gt;= 5 - &lt; 10 *</td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>No data available</td>
<td>58-93-5</td>
<td>&gt;= 5 - &lt; 10 *</td>
</tr>
</tbody>
</table>

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed:
May damage the unborn child.
Causes damage to organs through prolonged or repeated exposure.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aider

First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician

Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media

- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media

- None known.

Specific hazards during fire fighting

- Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
- Exposure to combustion products may be a hazard to health.

Hazardous combustion products

- Carbon oxides
- Nitrogen oxides (NOx)
- Chlorine compounds
- Sulfur oxides

Specific extinguishing methods

- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

Special protective equipment for fire-fighters

- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions

- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spills cannot be contained.

Methods and materials for containment and cleaning up

- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
SAFETY DATA SHEET

Olmesartan / Hydrochlorothiazide Formulation

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage: Keep in properly labeled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents Organic peroxides Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olmesartan</td>
<td>144689-63-4</td>
<td>TWA</td>
<td>30 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>300 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>CA AB OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Total dust)</td>
<td>10 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (respirable dust fraction)</td>
<td>3 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWAEV (to-)</td>
<td>10 mg/m³</td>
<td>CA QC OEL</td>
</tr>
</tbody>
</table>

Date of last issue: 10/10/2020
Date of first issue: 01/07/2016
### Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

### Personal protective equipment

**Respiratory protection**
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- **Filter type**: Particulates type
- **Hand protection**: Chemical-resistant gloves

**Eye protection**
- Wearing safety glasses with side shields or goggles.
- If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
- Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection**
- Work uniform or laboratory coat.
- Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
- Use appropriate degowning techniques to remove potentially contaminated clothing.

**Hygiene measures**
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

**Appearance**
- powder

**Color**
- white to off-white

**Odor**
- No data available
Odor Threshold : No data available
pH : No data available
Melting point/freezing point : No data available
Initial boiling point and boiling range : No data available
Flash point : Not applicable
Evaporation rate : Not applicable
Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids) : No data available
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapor pressure : Not applicable
Relative vapor density : Not applicable
Relative density : No data available
Density : No data available
Solubility(ies)
   Water solubility : No data available
Partition coefficient: n-octanol/water : Not applicable
Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity
   Viscosity, kinematic : Not applicable
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : Not applicable
Particle size : No data available
Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions:
   - May form explosive dust-air mixture during processing, handling or other means.
   - Can react with strong oxidizing agents.

Conditions to avoid:
   - Heat, flames and sparks.
   - Avoid dust formation.

Incompatible materials:
   - Oxidizing agents

Hazardous decomposition products:
   - No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 5,000 mg/kg
   Method: Calculation method

Components:

Olmesartan:
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
                   LD50 (Mouse): > 2,000 mg/kg
                   LD50 (Dog): > 1,500 mg/kg

Acute inhalation toxicity: Remarks: No data available

Acute dermal toxicity: Remarks: No data available

Cellulose:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity: LC50 (Rat): > 5.8 mg/l
   Exposure time: 4 h
   Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg

Hydrochlorothiazide:
Acute oral toxicity: LD50 (Rat): > 2,750 mg/kg
                  LD50 (Mouse): > 2,830 mg/kg
**Acute toxicity (other routes of administration)**

- **LD50 (Rat):** 990 mg/kg  
  Application Route: Intravenous
- **LD50 (Mouse):** 590 mg/kg  
  Application Route: Intravenous

**Skin corrosion/irritation**

Not classified based on available information.

**Components:**

- **Olmesartan:**
  - Remarks: No data available

- **Hydrochlorothiazide:**
  - Species: Rabbit
  - Result: No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:**

- **Olmesartan:**
  - Species: Rabbit
  - Result: Moderate eye irritation
  - Method: Draize Test

- **Hydrochlorothiazide:**
  - Species: Rabbit
  - Result: Mild eye irritation

**Respiratory or skin sensitization**

**Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Components:**

- **Olmesartan:**
  - Routes of exposure: Skin contact
  - Remarks: No data available

**Germ cell mutagenicity**

Not classified based on available information.
### Genotoxicity in vitro

**Olmesartan / Hydrochlorothiazide Formulation**

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type: Bacterial reverse mutation assay (AMES)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Result: negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type: Mutagenicity (in vitro mammalian cytogenetic test)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Result: negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type: Chromosome aberration test in vitro</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Test system: Chinese hamster lung cells</td>
</tr>
<tr>
<td></td>
<td>Result: positive</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type: Mouse Lymphoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Result: negative</td>
</tr>
</tbody>
</table>

### Genotoxicity in vivo

<table>
<thead>
<tr>
<th>Genotoxicity in vivo</th>
<th>Test Type: Micronucleus test</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Species: Mouse</td>
</tr>
<tr>
<td></td>
<td>Cell type: Bone marrow</td>
</tr>
<tr>
<td></td>
<td>Application Route: Oral</td>
</tr>
<tr>
<td></td>
<td>Result: negative</td>
</tr>
</tbody>
</table>

### Germ cell mutagenicity - Assessment

**Weight of evidence does not support classification as a germ cell mutagen.**

### Cellulose

**Genotoxicity in vitro**

- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative

- Test Type: In vitro mammalian cell gene mutation test
  - Result: negative

**Genotoxicity in vivo**

- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - Species: Mouse
  - Application Route: Ingestion
  - Result: negative

### Hydrochlorothiazide

**Genotoxicity in vitro**

- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative

- Test Type: Chromosomal aberration
  - Test system: Chinese hamster ovary cells
  - Result: negative

- Test Type: sister chromatid exchange assay
  - Test system: Chinese hamster ovary cells
  - Result: positive

- Test Type: in vitro test
  - Test system: mouse lymphoma cells
  - Result: positive

**Genotoxicity in vivo**

- Test Type: Chromosomal aberration
  - Species: Chinese hamster
  - Cell type: Bone marrow
Germ cell mutagenicity - Germ cell mutagenicity - Assessment: Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.

Components:

Olmesartan:
Species: Rat
Application Route: Oral
Exposure time: 2 Years
Result: negative
Species: Mouse
Application Route: Oral
Exposure time: 6 Months
Result: negative

Cellulose:
Species: Rat
Application Route: Ingestion
Exposure time: 72 weeks
Result: negative

Hydrochlorothiazide:
Species: Mouse, female
Application Route: Oral
Exposure time: 2 Years
Result: negative
Species: Mouse, male
Application Route: Oral
Exposure time: 2 Years
Result: equivocal
Species: Rat, male and female
Application Route: Oral
Exposure time: 2 Years
Result: negative

Reproductive toxicity
May damage the unborn child.
Components:

Olmesartan:

Effects on fertility:
- Test Type: Fertility
  - Species: Rat
  - Application Route: Oral
  - Fertility: NOAEL: 1,000 mg/kg body weight
  - Result: No effects on fertility.

Effects on fetal development:
- Test Type: Development
  - Species: Rat
  - Application Route: Oral
  - Dose: 1000 milligram per kilogram
  - Result: No teratogenic effects.
- Test Type: Development
  - Species: Rabbit
  - Application Route: Oral
  - Dose: 1 milligram per kilogram
  - Result: No teratogenic effects.
- Test Type: Development
  - Species: Rat
  - Application Route: Oral
  - Developmental Toxicity: LOAEL: >= 1.6 mg/kg body weight
  - Symptoms: Malformations were observed., Reduced body weight
  - Result: Effects on postnatal development.

Reproductive toxicity - Assessment:
- Positive evidence of adverse effects on development from human epidemiological studies.

Cellulose:

Effects on fertility:
- Test Type: One-generation reproduction toxicity study
  - Species: Rat
  - Application Route: Ingestion
  - Result: negative

Effects on fetal development:
- Test Type: Fertility/early embryonic development
  - Species: Rat
  - Application Route: Ingestion
  - Result: negative

Hydrochlorothiazide:

Effects on fertility:
- Test Type: Fertility
  - Species: Rat, male and female
  - Application Route: oral (feed)
  - Fertility: NOAEL: 4 mg/kg body weight
  - Result: Effects on fertility.
- Test Type: Fertility
  - Species: Mouse, male and female
  - Application Route: oral (feed)
  - Fertility: NOAEL: 100 mg/kg body weight
Result: Effects on fertility.

Effects on fetal development: Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 3,000 mg/kg body weight
Result: No teratogenic effects.

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
Result: No teratogenic effects.

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
Causes damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.

Components:

Hydrochlorothiazide:
Target Organs: Kidney, Parathyroid gland
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Olmesartan:
Species: Rat
NOAEL: 2,000 mg/kg
Application Route: Oral
Exposure time: 24 Months
Remarks: No significant adverse effects were reported

Cellulose:
Species: Rat
NOAEL: &ge; 9,000 mg/kg
Application Route: Ingestion
Exposure time: 90 Days

Hydrochlorothiazide:
Species: Rat, male and female
LOAEL: 10 mg/kg
Application Route: Oral
Exposure time: 2 y
Target Organs: Kidney, Parathyroid gland
Species: Mouse, male and female
NOAEL: 300 - 550 mg/kg
### Application Route
- Oral

### Exposure time
- 2 y

### Remarks
- No significant adverse effects were reported

### Species
- Dog

### Application Route
- Oral

### Exposure time
- 9 Months

### Target Organs
- Parathyroid gland

---

**Aspiration toxicity**
Not classified based on available information.

**Components:**

**Hydrochlorothiazide:**
No aspiration toxicity classification

**Experience with human exposure**

**Components:**

**Olmesartan:**
- **Eye contact:**
  - Symptoms: Eye irritation
- **Ingestion:**
  - Symptoms: hypotension
  - Remarks: May cause harm to the unborn child.
  - Based on Human Evidence

**Hydrochlorothiazide:**
- **Eye contact:**
  - Symptoms: Eye irritation
- **Ingestion:**
  - Symptoms: Dizziness, Headache, Fatigue, Nausea, Abdominal pain, hypotension, dry mouth, electrolyte imbalance, eye pain

---

**SECTION 12. ECOLOGICAL INFORMATION**

**Ecotoxicity**

**Components:**

**Cellulose:**
- **Toxicity to fish:**
  - LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
  - Exposure time: 48 h
  - Remarks: Based on data from similar materials

**Hydrochlorothiazide:**
- **Toxicity to fish:**
  - LC50 (Pimephales promelas (fathead minnow)): > 500 mg/l
  - Exposure time: 96 h

- **Toxicity to daphnia and other aquatic invertebrates:**
  - EC50 (Daphnia magna (Water flea)): > 500 mg/l
  - Exposure time: 48 h
Persistence and degradability

Components:

Cellulose:
Biodegradability: Result: Readily biodegradable.

Hydrochlorothiazide:
Stability in water: Hydrolysis: 46.2 % (96 h)

Bioaccumulative potential
No data available

Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

TDG
Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
CA BC OEL : Canada. British Columbia OEL
CA QC OEL : Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
ACGIH / TWA : 8-hour, time-weighted average
CA AB OEL / TWA : 8-hour Occupational exposure limit
CA BC OEL / TWA : 8-hour time weighted average
CA QC OEL / TWAEV : Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.5</td>
<td>04/09/2021</td>
<td>402475-00013</td>
<td>10/10/2020</td>
<td>01/07/2016</td>
</tr>
</tbody>
</table>

Revision Date : 04/09/2021  
Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8